Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Carrozzi

Showing results (61-70 of 110) with videos related to

Pageof 11
Sort By:
Thorax|April 6, 2017
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trialEugenio Paci, Donella Puliti, Andrea Lopes Pegna, et al.
Frontiers in Immunology|February 10, 2022
Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19?Federica Saponaro, Maria Franzini, Chukwuma Okoye, et al.
Lung Cancer (Amsterdam, Netherlands)|August 30, 2008
Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CTAndrea Lopes Pegna, Giulia Picozzi, Mario Mascalchi, et al.
International Journal of Cancer|April 8, 2017
Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker studyFrancesca Maria Carozzi, Simonetta Bisanzi, Laura Carrozzi, et al.
Epidemiologia E Prevenzione|November 13, 2014
[Tobacco taxation is a public health measure]Silvano Gallus, Giuseppe Gorini, Lorenzo Spizzichino, et al.
RMD Open|January 10, 2025
Anticoagulation in venous thromboembolism in Behçet's syndrome: friend or foe?Elisabetta Casto, Alessandro Celi, Rosalinda Madonna, et al.
Orphanet Journal of Rare Diseases|January 20, 2026
Epidemiology of idiopathic pulmonary fibrosis: a population registry-based studyGorini Francesca, Santoro Michele, Pierini Anna, et al.
Inflammopharmacology|August 3, 2023
Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effectsMarco Di Battista, Laura Tavanti, Francesco Pistelli, et al.
Respiratory Medicine|January 13, 2021
Suggestions for lung function testing in the context of COVID-19Manlio Milanese, Angelo Guido Corsico, Salvatore Bellofiore, et al.
Joint Bone Spine|June 26, 2025
Quantitative HRCT as a surrogate outcome measure for nintedanib treatment in systemic sclerosis-interstitial lung disease and idiopathic pulmonary fibrosisMarco Di Battista, Chiara Romei, Laura Tavanti, et al.
Pageof 11

Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
Thorax|April 6, 2017
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trialEugenio Paci, Donella Puliti, Andrea Lopes Pegna, et al.
Frontiers in Immunology|February 10, 2022
Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19?Federica Saponaro, Maria Franzini, Chukwuma Okoye, et al.
Lung Cancer (Amsterdam, Netherlands)|August 30, 2008
Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CTAndrea Lopes Pegna, Giulia Picozzi, Mario Mascalchi, et al.
International Journal of Cancer|April 8, 2017
Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker studyFrancesca Maria Carozzi, Simonetta Bisanzi, Laura Carrozzi, et al.
Epidemiologia E Prevenzione|November 13, 2014
[Tobacco taxation is a public health measure]Silvano Gallus, Giuseppe Gorini, Lorenzo Spizzichino, et al.
RMD Open|January 10, 2025
Anticoagulation in venous thromboembolism in Behçet's syndrome: friend or foe?Elisabetta Casto, Alessandro Celi, Rosalinda Madonna, et al.
Orphanet Journal of Rare Diseases|January 20, 2026
Epidemiology of idiopathic pulmonary fibrosis: a population registry-based studyGorini Francesca, Santoro Michele, Pierini Anna, et al.
Inflammopharmacology|August 3, 2023
Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effectsMarco Di Battista, Laura Tavanti, Francesco Pistelli, et al.
Respiratory Medicine|January 13, 2021
Suggestions for lung function testing in the context of COVID-19Manlio Milanese, Angelo Guido Corsico, Salvatore Bellofiore, et al.
Joint Bone Spine|June 26, 2025
Quantitative HRCT as a surrogate outcome measure for nintedanib treatment in systemic sclerosis-interstitial lung disease and idiopathic pulmonary fibrosisMarco Di Battista, Chiara Romei, Laura Tavanti, et al.
Pageof 11